Effects of Metformin on Survival and Toxicity in Patients with Metastatic Non-Small Cell Lung Cancer Treated with Nivolumab
<i>Background and Objectives:</i> This study evaluated the effects of concurrent metformin use on clinical outcomes in patients with metastatic non-small cell lung cancer (NSCLC) treated with nivolumab. <i>Materials and Methods:</i> A total of 152 patients were analyzed, incl...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-06-01
|
| Series: | Medicina |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1648-9144/61/7/1161 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | <i>Background and Objectives:</i> This study evaluated the effects of concurrent metformin use on clinical outcomes in patients with metastatic non-small cell lung cancer (NSCLC) treated with nivolumab. <i>Materials and Methods:</i> A total of 152 patients were analyzed, including 110 non-users and 42 metformin users with type 2 diabetes. <i>Results:</i> A significant gender imbalance was observed, with a higher proportion of females in the metformin group (33.3% vs. 8.2%, <i>p</i> < 0.05). The metformin group showed a numerically higher body mass index (BMI), though not statistically significant (26.53 vs. 24.97, <i>p</i> = 0.065). Overall survival was significantly longer in the metformin group (5.02 ± 3.93 vs. 4.6 ± 3.79 years, <i>p</i> < 0.05), while progression-free survival did not differ significantly (1.32 ± 0.97 vs. 1.04 ± 0.75 years, <i>p</i> = 0.385). Although most adverse events were similar across groups, grade 3–4 thrombocytopenia was more frequent in metformin users (<i>p</i> < 0.05). Multivariate analysis showed that increased nivolumab treatment cycles were significantly associated with reduced mortality risk (OR = 0.64, 95% CI: 0.54–0.75, <i>p</i> < 0.05). <i>Conclusions:</i> These findings suggest that concurrent metformin use may enhance overall survival but also increase hematologic toxicity, warranting closer monitoring in NSCLC patients receiving nivolumab. |
|---|---|
| ISSN: | 1010-660X 1648-9144 |